Tags

Type your tag names separated by a space and hit enter

Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
Expert Rev Clin Pharmacol 2014; 7(5):623-31ER

Abstract

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age. It is characterized by chronic anovulation, hyperandrogenism, and insulin resistance. It is the main cause of infertility due to the menstrual dysfunction and metabolic disorders. Women with PCOS also have an increased cardiovascular risk because of dyslipidemia and insulin resistance. So far, we have a lot of information about the etiology of PCOS, and many steps forward have been made about the diagnosis of this syndrome, but there is still no certainty about the therapy. Myo-inositol (MI) and D-chiro-inositol, two inositol stereoisomers, have been proven to be effective in PCOS treatment. However, only MI has been shown to have beneficial effects on reproductive function, whereas the administration of MI/D-chiro-inositol, in the physiological plasma ratio (i.e., 40:1) ensures better clinical results, such as the reduction of insulin resistance, androgens' blood levels, cardiovascular risk and regularization of menstrual cycle with spontaneous ovulation.

Authors+Show Affiliations

A.G.UN.CO. Obstetric and Gynecological Centre, via G. Cassiani 15, 00155 Rome, Italy.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

24898153

Citation

Unfer, Vittorio, and Giuseppina Porcaro. "Updates On the Myo-inositol Plus D-chiro-inositol Combined Therapy in Polycystic Ovary Syndrome." Expert Review of Clinical Pharmacology, vol. 7, no. 5, 2014, pp. 623-31.
Unfer V, Porcaro G. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2014;7(5):623-31.
Unfer, V., & Porcaro, G. (2014). Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome. Expert Review of Clinical Pharmacology, 7(5), pp. 623-31. doi:10.1586/17512433.2014.925795.
Unfer V, Porcaro G. Updates On the Myo-inositol Plus D-chiro-inositol Combined Therapy in Polycystic Ovary Syndrome. Expert Rev Clin Pharmacol. 2014;7(5):623-31. PubMed PMID: 24898153.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome. AU - Unfer,Vittorio, AU - Porcaro,Giuseppina, Y1 - 2014/06/05/ PY - 2014/6/6/entrez PY - 2014/6/6/pubmed PY - 2015/3/31/medline KW - infertility KW - inositol KW - insulin resistance KW - oocyte KW - polycystic ovarian syndrome SP - 623 EP - 31 JF - Expert review of clinical pharmacology JO - Expert Rev Clin Pharmacol VL - 7 IS - 5 N2 - Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age. It is characterized by chronic anovulation, hyperandrogenism, and insulin resistance. It is the main cause of infertility due to the menstrual dysfunction and metabolic disorders. Women with PCOS also have an increased cardiovascular risk because of dyslipidemia and insulin resistance. So far, we have a lot of information about the etiology of PCOS, and many steps forward have been made about the diagnosis of this syndrome, but there is still no certainty about the therapy. Myo-inositol (MI) and D-chiro-inositol, two inositol stereoisomers, have been proven to be effective in PCOS treatment. However, only MI has been shown to have beneficial effects on reproductive function, whereas the administration of MI/D-chiro-inositol, in the physiological plasma ratio (i.e., 40:1) ensures better clinical results, such as the reduction of insulin resistance, androgens' blood levels, cardiovascular risk and regularization of menstrual cycle with spontaneous ovulation. SN - 1751-2441 UR - https://www.unboundmedicine.com/medline/citation/24898153/Updates_on_the_myo_inositol_plus_D_chiro_inositol_combined_therapy_in_polycystic_ovary_syndrome_ L2 - http://www.tandfonline.com/doi/full/10.1586/17512433.2014.925795 DB - PRIME DP - Unbound Medicine ER -